Business Context and Reporting Period
This Form 8-K reports on the results of the 2023 Annual Meeting of Stockholders held by Leap Therapeutics, Inc. on June 16, 2023. The filing also details a subsequent corporate action regarding the conversion of preferred stock on June 21, 2023. Note: The request metadata lists "CYPHERPUNK TECHNOLOGIES INC.", but the filing text explicitly identifies the registrant as Leap Therapeutics, Inc.
Key Financial Metrics
This filing is a Current Report regarding corporate governance and capital structure events. It does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The only quantitative financial data presented relates to voting totals and share counts.
Material Changes and Corporate Actions
- Director Elections: Joseph Loscalzo, Nissim Mashiach, and Christopher Mirabelli were elected as Class III directors.
- Executive Compensation: Stockholders approved the advisory vote on executive compensation and mandated that future advisory votes occur annually.
- Equity Plan: The Amendment to the 2022 Equity Incentive Plan was approved.
- Accounting Firm: EisnerAmper LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
- Capital Structure: Stockholders approved the issuance of common stock upon the conversion of Series X Non-Voting Convertible Preferred Stock and a reverse stock split.
- Share Count Update: Following the conversion of Series X Preferred Stock and the reverse stock split on June 21, 2023, there are 24,005,499 shares of common stock issued and outstanding.
Guidance, Outlook, and Risks
The filing contains no management commentary on business outlook, financial guidance, or specific risk factors. The primary operational update is the confirmation of the annual frequency for executive compensation advisory votes until 2029, unless the Board determines otherwise.
Investor Verification Checklist
- Verify the impact of the reverse stock split on the price per share and trading volume on the Nasdaq Capital Market.
- Confirm the final share count of 24,005,499 in subsequent filings (e.g., 10-Q or 10-K).
- Review the specific terms of the approved Amendment to the 2022 Equity Incentive Plan for potential dilution effects.
- Monitor the transition of the independent auditor to EisnerAmper LLP for the 2023 fiscal year.